Tagged With Biotech

Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer


Dispensed: The inside story of uBiome, a visit to the largest health system in New York, and what it's like to take a 'biotech for dummies' course


We took the two-day, $1,300 'biotech for dummies' class where healthcare executives, HR managers, and investors catch up on science for the first time since high school



Why everybody gets duped by hot health and science startups


Dispensed: A record-breaking approval, what it's like to work in healthcare, and a call for nominations


The inside story of how the Silicon Valley burger startup Impossible Foods is going global after its sizzling Burger King debut



Digital health startups worth $7.6 billion are set to IPO, breaking a 3-year drought. Here's what 5 top VCs are keeping an eye on.


Dispensed: Troubles at uBiome, pharma giant Merck's plan to upend the $20 billion HIV market, and why insurers are starting to embrace brands like SmileDirectClub


The doctor who helped create a skin-care line for Amazon just started a new website to take on drug companies that charge $2,000 for common creams


There's now a cure for the deadly genetic disorder known as 'bubble-boy' disease


The IPO market has come storming back. Nasdaq's head of healthcare listings gave us the lay of the land.


Outrage over the cost of the life-saving drug insulin has drugmakers scrambling, but Congress and the public demand a price cut



These powerful but little-known companies that have been blamed for high drug prices are now coming out of the shadows for a congressional interrogation


The top scientist at AveXis told us the 'unique' strength that powered its $9 billion sale to Novartis, and it could shape the future of gene therapy


The record breaking $74 billion BMS-Celgene takeover just got the green light from 2 key players


Bill Gates is worried about gene editing worsening inequality. Now a top ethicist is raising new red flags.



Biogen is crashing after scrapping its late-stage Alzheimer's drug trials


Silicon Valley startups backed by celebrities like Bill Gates are using gene-editing tool Crispr to make meat without farms — and to disrupt a $200 billion industry


Drugs that cost as much as a house are on the way to treat rare and devastating diseases. The US is scrambling to figure out how to pay for them.


Dispensed: Pharma CEOs on Capitol Hill, the exploding CBD market, and treating kids with new models of primary care